TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37364280

Group type: EXPERIMENTAL
Intervention: Thiamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37364283

Group type: EXPERIMENTAL
Intervention: Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37364590

Group type: EXPERIMENTAL
Intervention: CagriSema (cagrilintide 2·4 mg + semaglutide 2·4 mg)
Number of subjects: 92

Group type: COMPARATOR
Intervention: semaglutide (2·4 mg)
Number of subjects: 92

Group type: COMPARATOR
Intervention: cagrilintide (2·4 mg)
Number of subjects: 92
Study: 37364600

Group type: EXPERIMENTAL
Intervention: POSE 2.0
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lifestyle modification alone (Control)
Number of subjects: 42
Study: 37364669

Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 174

Group type: COMPARATOR
Intervention: 12-step facilitation (TSF)
Number of subjects: 174
Study: 37364683

Group type: EXPERIMENTAL
Intervention: 20-mg/d lutein supplementation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 37364684

Group type: EXPERIMENTAL
Intervention: Timely-unstable dietary pattern
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Super-delayed dietary pattern
Number of subjects: 781

Group type: COMPARATOR
Intervention: Timely-stable dietary pattern
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Delayed-stable dietary pattern
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Delayed-unstable dietary pattern
Number of subjects: 781
Study: 37364685

Group type: EXPERIMENTAL
Intervention: HYP-CT (Hypnosis-enhanced cognitive therapy)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 53
Study: 37364710

Group type: EXPERIMENTAL
Intervention: Ecnoglutide (subcutaneous injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37364721

Group type: EXPERIMENTAL
Intervention: Severe COVID-19 patients
Number of subjects: 153

Group type: COMPARATOR
Intervention: Moderate COVID-19 patients
Number of subjects: 153

Group type: COMPARATOR
Intervention: External cohort of 174 patients with comparable COVID-19 severities
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Unsupervised clustering based on 97 proteins with highest log2 fold changes
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Endotype 3
Number of subjects: 153
Study: 37365003

Group type: EXPERIMENTAL
Intervention: Short sleepers (<6 hours) without daytime sleepiness or sleep problems
Number of subjects: 740

Group type: COMPARATOR
Intervention: Short sleepers with daytime sleepiness and sleep problems
Number of subjects: 740
Study: 37365046

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM) combined with Collaborative Drug Therapy Management (CDTM)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group (BP monitor and instructions for HBPM)
Number of subjects: 322
Study: 37365154

Group type: EXPERIMENTAL
Intervention: Serum iron
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Transferrin saturation
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Hepcidin
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Inflammatory markers
Number of subjects: 278
Study: 37365210

Group type: EXPERIMENTAL
Intervention: Tablet-based system combining structured symptoms questionnaire and 2-handed spiral drawing
Number of subjects: 77

Group type: COMPARATOR
Intervention: Symptom questionnaire alone
Number of subjects: 77
Study: 37365374

Group type: EXPERIMENTAL
Intervention: Diet+EX (calorie restriction plus exercise training)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diet-ONLY (calorie restriction alone)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diet+EX
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diet-ONLY
Number of subjects: 16
Study: 37365439

Group type: EXPERIMENTAL
Intervention: Daily Examen
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Centering Prayer
Number of subjects: 71
Study: 37365483

Group type: EXPERIMENTAL
Intervention: FEC3-D3
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: AC4-D4
Number of subjects: 248
Study: 37365557

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination with 3+ doses
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Isolation from the source case
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Ventilation of indoor areas
Number of subjects: 611
Study: 37365575

Group type: EXPERIMENTAL
Intervention: Single-visit screen-and-treat (SV-SAT) approach using visual inspection with acetic acid (VIA) and thermal ablation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single-visit, screen-and-treat method using cryotherapy
Number of subjects: 10
Study: 37365583

Group type: EXPERIMENTAL
Intervention: LNA-i-miR-221 (5 mg/kg, 30-min IV infusion on 4 consecutive days)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: LNA-i-miR-221
Number of subjects: 17
Study: 37365596

Group type: EXPERIMENTAL
Intervention: Pyrotinib 400 mg daily plus letrozole 2.5 mg daily
Number of subjects: 53
Study: 37365597

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 302

Group type: COMPARATOR
Intervention: neoadjuvant chemotherapy (nCT)
Number of subjects: 302
Study: 37365608

Group type: EXPERIMENTAL
Intervention: Lp(a) ≥ 50 mg/dL in DM group
Number of subjects: 1543

Group type: COMPARATOR
Intervention: Lp(a) < 10 mg/dL in DM group
Number of subjects: 1543

Group type: EXPERIMENTAL
Intervention: Lp(a) ≥ 50 mg/dL in nonDM group
Number of subjects: 1543

Group type: COMPARATOR
Intervention: Lp(a) < 30 mg/dL in nonDM group
Number of subjects: 1543

Group type: EXPERIMENTAL
Intervention: DM with Lp(a) < 30 mg/dL
Number of subjects: 1543

Group type: EXPERIMENTAL
Intervention: DM with Lp(a) ≥ 30 mg/dL
Number of subjects: 1543
Study: 37365614

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Clinical research involvement
Number of subjects: 29
Study: 37365618

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg daily initiated at least 15 days before PCI and maintained until the end of follow-up.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no SGLT2i).
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Empagliflozin group.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 42
Study: 37365624

Group type: EXPERIMENTAL
Intervention: Hip-dominant Romanian deadlift (RDL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Knee-dominant Nordic hamstring exercise (NHE)
Number of subjects: 32
Study: 37365656

Group type: COMPARATOR
Intervention: Ask about tobacco use; advise to quit; assist with brief counseling (AAA) as standard care
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Ask; advise; connect to phone-based counseling (AAC)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: AAC + nicotine replacement therapy (NRT)
Number of subjects: 1500
Study: 37365665

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment (EBD/SEMS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical resection (SR)
Number of subjects: 40
Study: 37365881

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) containing drospirenone and ethinylestradiol (EE)
Number of subjects: 858

Group type: COMPARATOR
Intervention: Placebo COCs
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: COCs containing drospirenone and EE
Number of subjects: 858
Study: 37365922

Group type: EXPERIMENTAL
Intervention: UV irradiation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Melasma lesions (no UV exposure)
Number of subjects: 20
Study: 37365993

Group type: EXPERIMENTAL
Intervention: Essure
Number of subjects: 47
Study: 37366061

Group type: EXPERIMENTAL
Intervention: LVEF > 50%
Number of subjects: 33699

Group type: EXPERIMENTAL
Intervention: LVEF around 40% to 50%
Number of subjects: 33699

Group type: EXPERIMENTAL
Intervention: LVEF < 40%
Number of subjects: 33699

Group type: EXPERIMENTAL
Intervention: High-normal LVEF
Number of subjects: 33699

Group type: EXPERIMENTAL
Intervention: LVEF thresholds
Number of subjects: 33699
Study: 37366166

Group type: EXPERIMENTAL
Intervention: Step One intervention for traumatized children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addressing parents’ emotional reactions to a child's trauma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assistance for parents with lower education
Number of subjects: 0
Study: 37366170

Group type: EXPERIMENTAL
Intervention: Birtamimab 24 mg/kg IV + standard of care (SOC)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Birtamimab 24 mg/kg IV + SOC
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo + SOC
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Birtamimab + SOC
Number of subjects: 260
Study: 37366260

Group type: EXPERIMENTAL
Intervention: Occupational lead exposure
Number of subjects: 0
Study: 37366315

Group type: EXPERIMENTAL
Intervention: Retatrutide 1 mg
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Retatrutide 4 mg (combined initial doses of 2 mg and 4 mg)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Retatrutide 8 mg (combined initial doses of 2 mg and 4 mg)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Retatrutide 12 mg (initial dose of 2 mg)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 37366480

Group type: EXPERIMENTAL
Intervention: CPAP treatment for one year
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-adherent group
Number of subjects: 81
Study: 37366571

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 144

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 144
Study: 37366590

Group type: EXPERIMENTAL
Intervention: TV-45070, a topical semiselective sodium 1.7 channel (Nav1.7) blocker
Number of subjects: 294
Study: 37366614

Group type: EXPERIMENTAL
Intervention: Cefepime 2000 mg by 30-min intravenous infusions every 8 to 24 hours
Number of subjects: 14
Study: 37366668

Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF) therapy with immediate rinsing (Group A)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF) therapy with no rinsing for 30 min (Group B)
Number of subjects: 254
Study: 37366919

Group type: EXPERIMENTAL
Intervention: Burden of Therapy (BOTh) intervention
Number of subjects: 0
Study: 37367448

Group type: EXPERIMENTAL
Intervention: Multimodality US (including conventional US, strain elastography, and contrast-enhanced US)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Thyroid Imaging Reporting and Data System (TI-RADS)
Number of subjects: 434
Study: 37367978

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT): 300 mg clopidogrel on the first day followed by 75 mg daily for 12 days, 100 mg aspirin on the first day followed by 100 mg daily for 12 days, and guideline-based antiplatelet treatment until 90 days.
Number of subjects: 760

Group type: COMPARATOR
Intervention: Alteplase: intravenous alteplase (0.9 mg/kg; maximum dose, 90 mg) followed by guideline-based antiplatelet treatment beginning 24 hours after receipt of alteplase.
Number of subjects: 760
Study: 37368100

Group type: EXPERIMENTAL
Intervention: Adavosertib 225 mg twice daily on days 1-2 at 12-h intervals and once on day 3.
Number of subjects: 21
Study: 37368103

Group type: EXPERIMENTAL
Intervention: Risankizumab (RZB) 600 mg IV at weeks 0, 4, and 8
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risankizumab (RZB) 180 or 360 mg SC every 8 or 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab (UST) 6 mg/kg IV at week 0
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab (UST) 90 mg SC every 8 or 12 weeks
Number of subjects: 0
Study: 37368349

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 0
Study: 37368401

Group type: EXPERIMENTAL
Intervention: App-based individually tailored self-management support (SELFBACK) adjunct to usual care
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Web-based nontailored self-management support (e-Help) adjunct to usual care
Number of subjects: 294

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 294
Study: 37368507

Group type: EXPERIMENTAL
Intervention: Remote patient management (RPM)
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1538
Study: 37368512

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 5047

Group type: EXPERIMENTAL
Intervention: Lower insulin sensitivity
Number of subjects: 5047

Group type: EXPERIMENTAL
Intervention: Higher BMI (in models including both BMI and insulin sensitivity)
Number of subjects: 5047
Study: 37368517

Group type: EXPERIMENTAL
Intervention: Weight loss (LED)
Number of subjects: 50
Study: 37368522

Group type: EXPERIMENTAL
Intervention: Local review
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: SMART IRB agreement
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: IRB authorization agreement
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Letter of support
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Midwestern sites
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Western sites
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Northeastern sites
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Regulatory communication initiated after February 2019
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: R1 university affiliation
Number of subjects: 85
Study: 37368929

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) with oral etoposide chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiretroviral therapy (ART) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline serum biomarkers (CRP, IL-6, IL-10, soluble tumor necrosis factor receptor-2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantifying serum biomarkers (especially CRP)
Number of subjects: 0
Study: 37368931

Group type: EXPERIMENTAL
Intervention: Greater paraspinal muscle density (measured in Hounsfield units)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Greater paraspinal muscle area (cm²/m)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Lower thoracic paraspinal muscle density
Number of subjects: 708
Study: 37368992

Group type: EXPERIMENTAL
Intervention: Group A Streptococcus rapid antigen detection test
Number of subjects: 256
Study: 37369081

Group type: EXPERIMENTAL
Intervention: EV + Pembro
Number of subjects: 149

Group type: COMPARATOR
Intervention: EV monotherapy
Number of subjects: 149
Study: 37369096

Group type: EXPERIMENTAL
Intervention: +2.50-D add multifocal contact lenses
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: +1.50-D add multifocal contact lenses
Number of subjects: 3

Group type: COMPARATOR
Intervention: Single-vision contact lenses
Number of subjects: 3
Study: 37369099

Group type: EXPERIMENTAL
Intervention: R-CHOP-tafasitamab (arm T)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: R-CHOP-tafasitamab-lenalidomide (arm T/L)
Number of subjects: 66
Study: 37369125

Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg/day for 1 week
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 32
Study: 37369232

Group type: EXPERIMENTAL
Intervention: Orforglipron (12 mg or greater)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383

Group type: COMPARATOR
Intervention: Dulaglutide
Number of subjects: 383
Study: 37369239

Group type: EXPERIMENTAL
Intervention: nHFOV
Number of subjects: 133

Group type: COMPARATOR
Intervention: sNIPPV
Number of subjects: 133
Study: 37369338

Group type: EXPERIMENTAL
Intervention: Experimental Sleep Disturbance (ESD) protocol consisting of repeated nights of short and disrupted sleep with intermittent nights of undisturbed sleep, followed by three nights of recovery sleep.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control sleep condition with undisturbed sleep opportunity of 8 h/night throughout the protocol.
Number of subjects: 24
Study: 37369354

Group type: EXPERIMENTAL
Intervention: Breastmilk intake
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Energy intake from breastmilk
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Metabolizable energy (ME) content of breastmilk
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fat-free mass (FFM) z-score
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fat mass (FM) z-score
Number of subjects: 27
Study: 37369403

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) testing for malaria
Number of subjects: 1738

Group type: EXPERIMENTAL
Intervention: Testing by a CHW
Number of subjects: 1738

Group type: EXPERIMENTAL
Intervention: Awareness of local CHW
Number of subjects: 1738

Group type: EXPERIMENTAL
Intervention: Wealthiest households vs least wealthy
Number of subjects: 1738
Study: 37369408

Group type: EXPERIMENTAL
Intervention: Cochlear implantation (CI)
Number of subjects: 156
Study: 37369409

Group type: EXPERIMENTAL
Intervention: MGPOCUS-guided bronchoscope
Number of subjects: 108

Group type: COMPARATOR
Intervention: Bronchoscope
Number of subjects: 108
Study: 37369412

Group type: EXPERIMENTAL
Intervention: Music intervention (preferred recorded music before, during, and after the operation until day 3 after surgery)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group (standard clinical care)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 189
Study: 37369415

Group type: EXPERIMENTAL
Intervention: Routine childhood vaccinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetanus and MMR vaccinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMR2 and Tetanus boosters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preschool boosters (tetanus and MMR2)
Number of subjects: 0
Study: 37369421

Group type: EXPERIMENTAL
Intervention: high-velocity and articulation techniques
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: soft-tissue massage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: craniosacral techniques
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: combination of high-velocity, soft-tissue massage, and craniosacral techniques
Number of subjects: 30
Study: 37369422

Group type: EXPERIMENTAL
Intervention: 7 days antibiotic therapy
Number of subjects: 3626

Group type: COMPARATOR
Intervention: 14 days antibiotic therapy
Number of subjects: 3626
Study: 37369426

Group type: EXPERIMENTAL
Intervention: Conservative management (non-surgical group)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Surgical management (surgical group)
Number of subjects: 604
Study: 37369531

Group type: EXPERIMENTAL
Intervention: Hypoglycemia on day 1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycemia
Number of subjects: 21
Study: 37369550

Group type: EXPERIMENTAL
Intervention: v-TAC (venous to arterial conversion method)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABG (arterial blood gas sampling)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capillary blood gas (CBG) sampling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venous blood gas (VBG) sampling
Number of subjects: 0
Study: 37369551

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) defined as AHI ≥15 events/hour in patients with hypertension.
Number of subjects: 1927

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) in patients without hypertension.
Number of subjects: 1927

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) in patients with grade 3 hypertension.
Number of subjects: 1927

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) in patients with grade 1 or 2 hypertension.
Number of subjects: 1927
Study: 37369602

Group type: EXPERIMENTAL
Intervention: Intrathecal CD8
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flow cytometry assessments of blood and CSF CD20
Number of subjects: 0
Study: 37369815

Group type: EXPERIMENTAL
Intervention: IO-tyrosine kinase inhibitor (IO + TKI) combinations
Number of subjects: 729

Group type: COMPARATOR
Intervention: Dual immuno-oncology (IO + IO) therapy
Number of subjects: 729
Study: 37369826

Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg/day)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Basal long-acting insulin
Number of subjects: 301
Study: 37369832

Group type: EXPERIMENTAL
Intervention: Neonates with ASD
Number of subjects: 716

Group type: COMPARATOR
Intervention: Neonates without ASD (control)
Number of subjects: 716
Study: 37369852

Group type: EXPERIMENTAL
Intervention: Ropidoxuridine-capecitabine-radiotherapy
Number of subjects: 1
Study: 37369887

Group type: EXPERIMENTAL
Intervention: Patients informed of having a hernia on imaging results (occult hernias)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Patients informed of having a hernia on imaging results (clinical hernias)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Patients completing the follow-up survey before being informed of the hernia (occult hernias)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Patients completing the follow-up survey before being informed of the hernia (clinical hernias)
Number of subjects: 169
Study: 37369917

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Indexed volume of the proximal half of the thoracic aorta
Number of subjects: 79
Study: 37369955

Group type: EXPERIMENTAL
Intervention: Difelikefalin (single intravenous doses)
Number of subjects: 12
Study: 37369994

Group type: EXPERIMENTAL
Intervention: Digital innovation for clinical decision making in polypharmacy
Number of subjects: 218
Study: 37370032

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with mFOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan), up to 5 cycles.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with mFOLFOXIRI
Number of subjects: 50
Study: 37370055

Group type: EXPERIMENTAL
Intervention: Ntombi Vimbela! (NV!) intervention, comprising ten workshop sessions of 3.5 hours each, focusing on sexuality empowerment, gender and social norm change, early-risk identification, self-defence, resistance, and mental wellbeing.
Number of subjects: 98
Study: 37370064

Group type: EXPERIMENTAL
Intervention: Laser-treated healing abutment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Machined healing abutment (Control)
Number of subjects: 30